Barclays
COAG icon

Barclays’s Hemab Therapeutics COAG Stock Holding History

Barclays’s Portfolio COAG Stock Details COAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$236K Buy
7,664
+6,653
+658% +$292K ﹤0.01% 3865
2026
Q2 		$37.1K Buy
+1,011
New +$27.9K ﹤0.01% 4413

Other funds holding COAG

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Barclays's COAG Position: Q3 2026 in Review

Barclays increased its Hemab Therapeutics (COAG) stake by 658% in Q3 2026, buying an estimated $292K and bringing the position to 7,664 shares worth $236K. The position accounts for ﹤0.01% of the portfolio, ranked #3865.

Barclays first reported a position in COAG in Q2 2026 and has held it in 2 quarters since. 12 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

  • Barclays held 7,664 shares of Hemab Therapeutics worth $236K as of Q3 2026.
  • Barclays bought 6,653 Hemab Therapeutics shares in Q3 2026, an estimated $292K.
  • Hemab Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3865 holding.
  • Barclays first reported a position in Hemab Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 12 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.